Recently, Shanghai plans to set up three industrial pilot funds with a total scale of 89 billion yuan.

Stem cells are a type of cells that have the potential to self-renew and differentiate.

With the deepening of scientific research, stem cell technology is becoming more and more mature, and its application in medical and regenerative medicine has shown great potential.

TED-A9 is a midbrain dopaminergic progenitor cell derived from human embryonic stem cells (hESC), which can be used in the treatment of Parkinson's disease.

Premier Li Qiang presided over and approved the high-profile Implementation Plan for the Whole Chain to Support the development of Innovative Drugs.

As of June 30, 17 new stem cell drugs in China have been approved to enter clinical trials with tacit consent in 2024 (implicit approval for clinical trials), and 4 are being accepted.

The industry accelerates the layout of "cell intelligence" and enters the "fast lane".

Cell therapy will become one of the important methods of disease treatment in the future.